Nėra interneto ryšio – rodoma išsaugota puslapio versija.

10x Genomics, Inc…

USUSD
← Į Akcijų Filtrą
US:TXGLSE:0A88

10x Genomics, Inc. (LSE:0A88) — Biotechnology: Laboratory Analytical Instruments. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.

Apie Įmonę

Svetainė
10xgenomics.com
Sektorius
Industrials · Biotechnology: Laboratory Analytical Instruments
Būstinė
Pleasanton, United States
Generalinis Direktorius
Serge Saxonov
Darbuotojai
1 178
Įkurta
2012
Apyvartoje Esančios Akcijos
120.21 mln.
Laisvai Apyvartinės Akcijos
118.19 mln.
Rinkos Kapitalizacija
11.53 mlrd. USD
Insaideriai
1.46%
Instituciniai Investuotojai
120.2%
Šaka (SIC)
Laboratory Analytical Instruments
ISIN
US88025U1097
LEI
5493003Z6741WNLG7H43
FCF
121 mln. USD
Skola
0 USD
grynieji pinigai
Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
NAV
6.87 USD · P/NAV 12.9
Balanso Data30.06.2026
Turtas1.03 mlrd. USD
− Įsipareigojimai205 mln. USD
= NAV (įmonės akcininkų nuosavas kapitalas)826 mln. USD
− Prestižas6.92 mln. USD
− Nematerialusis Turtas61.2 mln. USD
= Materialioji NAV757 mln. USD
Akcijos120 212 296
NAV Vienai Akcijai6.87 USD
Apčiuopiamoji NAV Vienai Akcijai6.30 USD
Akcijos Kaina (0A88)88.3100 USD
P/NAV12.86
NAV Istorija
Balanso DataNAVNAV Vienai Akcijai
30.06.2026826 mln. USD6.87 USD
31.03.2026814 mln. USD6.77 USD
31.12.2025796 mln. USD6.24 USD
30.09.2025785 mln. USD6.53 USD
30.06.2025773 mln. USD6.43 USD
31.03.2025707 mln. USD5.88 USD
31.12.2024710 mln. USD5.81 USD
30.09.2024723 mln. USD6.01 USD
Aprašymas

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

reklama

Biržos ir Tikeriai

BiržaTikerisValiutaKainaTipas
US USA StocksTXG pagrindinisUSD72.39 -0.97%paprastosios akcijos
LSE London Stock Exchange0A88 IOBUSD88.31 +0.00%paprastosios akcijos

Kaina per 3 Mėnesius

kilimo diena kritimo dienaUžveskite / palieskite dieną — atidarymo, uždarymo, aukščiausia ir žemiausia kainos

Didžiausi Akcininkai

TurėtojasDalisAkcijosAtaskaitos Data
FMR, LLC14.67%17.63 mln.2026-06-30
Blackrock Inc.8.99%10.8 mln.2026-06-30
ARK Investment Managemen…8.32%10 mln.2026-06-30
Vanguard Portfolio Manag…5.81%6.98 mln.2026-06-30
Quantinno Capital Manage…4.55%5.47 mln.2026-06-30
Vanguard Capital Managem…4.23%5.08 mln.2026-06-30
Price (T.Rowe) Associate…3.78%4.54 mln.2026-06-30
Sumitomo Mitsui Trust Gr…3.49%4.19 mln.2026-06-30
Amova Asset Management A…3.49%4.19 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.94%3.53 mln.2026-06-30
Morgan Stanley2.79%3.35 mln.2026-06-30
iShares Trust-iShares Ru…2.53%3.04 mln.2026-07-31
ARK ETF Trust-ARK Genomi…2.53%3.04 mln.2026-08-31
ARK ETF Trust-ARK Innova…2.5%3.01 mln.2026-08-31
VANGUARD INDEX FUNDS-Van…2.12%2.55 mln.2026-06-30
Fidelity Select PORT.s-S…1.66%2 mln.2026-07-31
Fidelity Rutland Square…1.37%1.65 mln.2026-07-31
Fidelity Select Portfoli…1.34%1.61 mln.2026-07-31
VANGUARD INDEX FUNDS-Van…1.22%1.47 mln.2026-06-30
T. Rowe Price New Horizo…1.21%1.46 mln.2026-06-30
SAXONOV SERGE WILSON (Ch…≈1.11%1.34 mln.2026-09-22
HINDSON BENJAMIN J (Pres…≈0.41%488 1822026-08-24
STUELPNAGEL JOHN R (Dire…≈0.27%328 4362026-09-03
TAICH ADAM (Chief Financ…≈0.26%316 3442026-09-09
MATEO ALAN V. (Director)≈0.07%85 8772026-06-04
KOSARAJU SRIDHAR (Direct…≈0.06%68 2782026-06-04
POPOVITS KIMBERLY J (Dir…≈0.03%37 4452026-06-04
TEICHMANN SARAH A. (Dire…≈0.02%28 0582026-08-14
SULIMAN SHEHNAAZ (Direct…≈0.02%23 7922026-09-22